European Journal of Endocrinology (1999) 6
Key takeaways MeAgain is the GLP-1 progress tracker app where progress means more than weight: trend, photos, Journey Cards, dose context, food, side effects, protein, water, and medication-level context all sit on one timeline
in December 2028 may remain valid in Europe until 2031
Providing a two-fold benefit for individuals seeking to improve their physical fitness
While Tirzepatide produces impressive weight loss (up to about 21% at the highest dose), Retatrutides addition of glucagon receptor activation may further enhance fat metabolism, thermogenesis, and overall metabolic outcomes
Calcium citrate (not carbonate) absorbs better in the slower digestive environment semaglutide creates, making it a smarter choice than standard forms